NCT06495125View on ClinicalTrials.gov

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

March 17, 2028

Study Completion Date

September 17, 2028

Conditions
Advanced Lung AdenocarcinomaRefractory Lung AdenocarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Interventions
DRUG

Avutometinib

Given PO

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Defactinib

Given PO

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (3)

30308

NOT_YET_RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

RECRUITING

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER